UBS AM’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

UBS AM’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-49,289	Closed	-$329K	–	2621
2023 Q3	$329K	Buy	49,289 +30,751	+166%	+$256K	﹤0.01%	2410
2023 Q2	$135K	Hold	18,538	–	–	﹤0.01%	2614
2023 Q1	$135K	Sell	18,538 -18,200	-50%	-$135K	﹤0.01%	2614
2022 Q4	$268K	Hold	36,738	–	–	﹤0.01%	2362
2022 Q3	$284K	Buy	36,738 +3,438	+10%	+$29.2K	﹤0.01%	2508
2022 Q2	$227K	Buy	33,300 +15,100	+83%	+$116K	﹤0.01%	2556
2022 Q1	$145K	Hold	18,200	–	–	﹤0.01%	2709
2021 Q4	$102K	Buy	+18,200	New	+$137K	﹤0.01%	2818

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

UBS AM's PNT Position: Q4 2023 in Review

UBS AM sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 49,289 shares — an estimated $329K sold.

UBS AM first reported a position in PNT in Q4 2021 and held it in 8 quarters. The position peaked at $329K in Q3 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

UBS AM reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
UBS AM sold 49,289 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $329K.
UBS AM first reported a position in POINT Biopharma Global Inc. Common Stock in Q4 2021 and held it in 8 quarters.
UBS AM's POINT Biopharma Global Inc. Common Stock position peaked at $329K in Q3 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on UBS AM's 13F filing for Q4 2023, filed 14 Feb 2024.